Clinical Trials
121 trialsClinical Genetics Branch Eligibility Screening Survey
National Institutes of Health Clinical Center (CC)
FLASH Pilot Phase 1 Safety Study
Dartmouth-Hitchcock Medical Center
Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital
Ohio State University Comprehensive Cancer Center
TIRBACRYO
University Hospital, Lille
EPIBREAST
UNICANCER
UNIFIER
University of Florida
Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
Biocon Limited
Skin Subs vs Secondary Intention
Baylor Research Institute
IRIS
University of Pittsburgh
LANCE
Jules Bordet Institute
B3C
VA Office of Research and Development
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.
Swiss Cancer Institute
AI-enhanced OCT Imaging for Pre-surgical Margin Detection of Basal Cell Carcinoma
Henry Ford Health System
Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases
M.D. Anderson Cancer Center
BASIX
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
INFLECTION-003
Primmune Therapeutics, Inc.
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
Northwestern University
SESAME
Northwestern University
MagMen-II
Vastra Gotaland Region
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
Indiana University
ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1
University of Wisconsin, Madison
Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
University of California, Irvine
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.
Caja Costarricense de Seguro Social
NeoMatryx
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
Shanghai Jiao Tong University School of Medicine
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
Shanghai Henlius Biotech
Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial
University of Michigan Rogel Cancer Center
THERMS
Universitaire Ziekenhuizen KU Leuven
Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma
Shanghai Zhongshan Hospital
A Phase 2 Study of HW211026 in Participants With Actinic Keratosis
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
M.D. Anderson Cancer Center
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Biocon Limited
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients
University of Pittsburgh
TRIUMPH-AM
Shanghai Zhongshan Hospital
Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
Herlev Hospital
RELI
Maastricht University Medical Center
GAPIMET
University of Zurich
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
Rapa Therapeutics LLC
BCC-One-Stop-Study
University Hospital Augsburg
Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)
Case Comprehensive Cancer Center
A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma
Alvotech Swiss AG
REPLAY
Duke University
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Philogen S.p.A.
L19IL2/TNF in Patients With Basal Cell Carcinoma
Philogen S.p.A.
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Bristol-Myers Squibb
PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor
Peking University Cancer Hospital & Institute
FIBIOME
University Hospital, Grenoble